114833-95-3

Basic information

• Product Name: 4-Chloro-6-(1H-pyrazol-1-yl)pyrimidine
• Synonyms: 4-chloro-6-(1H-pyrazol-1-yl)pyrimidine(SALTDATA: FREE);1-(6-Chloropyrimidin-4-yl)-1H-pyrazole;4-Chloro-6-(1H-pyrazol-1-yl)pyrimidine98%
• CAS NO: 114833-95-3
• Molecular Formula: C₇H₅ClN₄
• Molecular Weight: 180.59
• Product Categories: blocks;Imidazoles;Pyridines
• Mol File: 114833-95-3.mol

Chemical Properties

• Melting Point: 128-129 °C(Solv: hexane (110-54-3))
• Boiling Point: 324.048 °C at 760 mmHg
• Flash Point: 149.779 °C
• Appearance: /
• Density: 1.475 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.702
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -2.69±0.19(Predicted)
• CAS DataBase Reference: 4-Chloro-6-(1H-pyrazol-1-yl)pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Chloro-6-(1H-pyrazol-1-yl)pyrimidine(114833-95-3)
• EPA Substance Registry System: 4-Chloro-6-(1H-pyrazol-1-yl)pyrimidine(114833-95-3)

Safety Data

• Hazardous Substances Data: 114833-95-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Chloro-6-(1H-pyrazol-1-yl)pyrimidine is used as a key intermediate in the synthesis of pharmaceuticals for its ability to be incorporated into the molecular structures of potential drugs. Its unique substitution pattern allows for the creation of novel compounds with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 4-Chloro-6-(1H-pyrazol-1-yl)pyrimidine is utilized as a precursor in the development of new pesticides or other agrochemicals, leveraging its chemical reactivity and structural features to enhance crop protection and yield.
Used in Materials Science:
4-Chloro-6-(1H-pyrazol-1-yl)pyrimidine is used as a component in the research and development of new materials, potentially contributing to advances in areas such as polymers, coatings, or composites due to its chemical versatility.
Used in Organic Electronics:
4-Chloro-6-(1H-pyrazol-1-yl)pyrimidine is also used in the field of organic electronics, where its electronic properties may be harnessed for applications in organic light-emitting diodes (OLEDs), organic photovoltaics, or other electronic devices that benefit from organic materials' unique characteristics.

InChI:InChI=1/C7H5ClN4/c8-6-4-7(10-5-9-6)12-3-1-2-11-12/h1-5H

Upstream product

• 288-13-1 NH-pyrazole 
• 1193-21-1 4,6-dichloropyrimidine 

Downstream Products

• 114834-09-2 6-(1H-pyrazol-1-yl)pyrimidin-4-amine 
• 82892-95-3 4-(1'-pyrazolyl)pyrimidine 

Relevant articles and documents

Development of Multifunctional Pyrimidinylthiourea Derivatives as Potential Anti-Alzheimer Agents

Starting from a screening-hit compound, via structure modifications and optimizations, a series of nonfused and nonassembly pyrimidinylthiourea derivatives (2-5) was designed, synthesized, and evaluated as novel multifunctional agents against Alzheimer's disease. Biological activity results demonstrated that compounds 5r and 5t exhibited potent inhibition and excellent selectivity toward acetylcholinesterase (AChE, 5r, IC50 = 0.204 μM, SI > 196; 5t, IC50 = 0.067 μM, SI > 597), specific metal-chelating ability, significant antioxidant effects, modulation of metal-induced Aβ aggregation, inhibition of ROS production by copper redox cycle, low cytotoxicity, and moderate neuroprotection to human neuroblastoma SH-SY5Y cells. Moreover, compound 5r displayed appropriate blood-brain barrier (BBB) permeability both in vitro and in vivo and could improve memory and cognitive function of scopolamine-induced amnesia mice. The multifunctional profiles of 5r and its effectivity in AD mice highlight these structurally distinct pyrimidinylthiourea derivatives as prospective prototypes in the research of innovative multifunctional drugs for Alzheimer's disease.

BMS-933043, a Selective α7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with Schizophrenia

The therapeutic treatment of negative symptoms and cognitive dysfunction associated with schizophrenia is a significant unmet medical need. Preclinical literature indicates that α7 neuronal nicotinic acetylcholine (nACh) receptor agonists may provide an effective approach to treating cognitive dysfunction in schizophrenia. We report herein the discovery and evaluation of 1c (BMS-933043), a novel and potent α7 nACh receptor partial agonist with high selectivity against other nicotinic acetylcholine receptor subtypes (>100-fold) and the 5-HT3A receptor (>300-fold). In vivo activity was demonstrated in a preclinical model of cognitive impairment, mouse novel object recognition. BMS-933043 has completed Phase I clinical trials.

SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF

The present invention covers substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular and renal diseases, as a sole agent or in combination with other active ingredients.

Α 7 as intranuclear hydroxynicotinic acetylcholine receptor quinuclidines compd.

PROBLEM TO BE SOLVED: To provide ligands for the nicotinic α-7 receptor used for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.SOLUTION: The disclosure provides compounds of the specified formula I, including their salts, and compositions and methods using the compounds.

Synthesis and cytoprotective antiulcer activity of 2- or 4-(1H-pyrazol- 1-yl)pyrimidine derivatives related to mepirizole and dulcerozine

(1H-Pyrazol-1-yl)-, (1H-imidazol-1-yl)-, and (1H-1,2,4-triazol-1- yl)pyrimidines were prepared and evaluated for cytoprotective antiulcer activity. Among them, 4-methoxy-6-methyl-2-(1H-pyrazol-1-yl)pyrimidine (18) showed potent inhibition of the HCl-ethanol-induced and water-immersion stress-induced ulcers in rats, as well as low acute toxicity.

SYNTHESES OF NEW PYRAZOLE-DERIVED CHELATING LIGANDS

The preparations and spectral data for nine new N,N'-chelating ligands (5)-(13), each consisting of a pyrazole group N-linked to an azine or azole, are described.

Pyrimidine derivatives

The present invention relates to novel pyrimidine derivatives of the general formula STR1 wherein R1 represents a pyrazolyl, imidazolyl, or triazolyl group, R2 represents hydrogen atom or lower alkyl group, R3 represents a halo, amino, lower alkoxy, pyrazolyl, imidazolyl, triazolyl, piperidinyl, or aryloxy group, one of X or Y represents N and the other of X or Y represents CH, and the salts thereof. These derivatives may be used in the treatment of peptic ulcer disease.